For research use only
| Cat No. | ABC-SC0020T |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Foreskin |
| Disease | Niemann Pick Type C |
| Storage | Liquid Nitrogen |
Leverage HighQC™ Human IPSC From Foreskin Fibroblast (Morbus Niemann Pick Type C) to study NPC pathogenesis and evaluate potential therapeutic strategies.
HighQC™ Human iPSCs From Foreskin Fibroblasts (Morbus Niemann Pick Type C) is an induced pluripotent stem cell line reprogrammed from human foreskin fibroblasts of an 11-year-old male Morbus Niemann-Pick Type C patient. The cell line was generated via episomal reprogramming using a proprietary mix of vectors, containing OCT4, SOX2, KLF4, p53 antisense, and EBNA-1, preserving genomic integrity. The cell line was validated for pluripotency based on classical colony morphology, alkaline phosphatase expression, and high expression of key pluripotency markers including SSEA-4. It exhibits classical pluripotent stem cell morphology and robust growth, and can differentiate into cells/tissues of all three germ layers. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human IPSC From Foreskin Fibroblast (Morbus Niemann Pick Type C), Human iPSC-Fib-NPC, hIPSC-Fib-NPC, Human Foreskin Fibroblast Derived iPSC Niemann Pick |
| Species | Human |
| Cat.No | ABC-SC0020T |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Foreskin |
| Disease | Niemann Pick Type C |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSCs From Foreskin Fibroblasts (Morbus Niemann Pick Type C) serve as a physiologically relevant in vitro model for Niemann-Pick type C (NPC) disease mechanism investigation and drug screening applications. Researchers can utilize this platform for high-throughput compound screening to identify candidate compounds that restore cholesterol homeostasis, as well as for CRISPR-based gene editing studies to validate disease-associated molecular pathways. The model supports both mechanistic studies and preclinical evaluation of potential research applications.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).